Unison Medicines is delighted to announce an oversubscribed first close of $500k of financing from a syndicate of highly sophisticated biopharma angels. Unison will use the proceeds to conduct a series of animal studies of its novel RecA inhibitor lead series, which is active against E. coli. These animal studies are intended to enable a planned second close on the balance of $4 million of financing later in 2025.

Unison Medicines is a biotechnology company focused on discovering and developing first-in-class medicines for the front-line treatment of bacterial infections. The company targets bacterial stress responses, effectively shutting down bacterial defenses. Its medicines are designed to serve as potentiators for currently approved drugs — restoring the efficacy of inexpensive generics — or as single agents that enhance the immune system while remaining gentle to the microbiome.

Unison’s pipeline consists of small molecules that are patient-friendly and enable efficient manufacturing and distribution. The company collaborates with leading drug discovery experts worldwide. Spun out of MIT, Unison Medicines is headquartered in Cambridge, Massachusetts.

A post by Unison Medicines

Just like Unison Medicines, INCATE encourages all our ventures to share their exciting opportunities, connections, and milestones. We’d love to hear from you!

Reach out to us at comms@incate.net and let us know what you’ve been up to.